There is a growing body of evidence confirming the benefit of targeting the IL-6 pathway in patients with COVID-19, most notably in a recent single-arm study in China with tocilizumab in critically ill COVID-19 patients [94]. The gene discussed is IL6; the disease is COVID-19.